Background: Although it is well established that the extracellular matrix affects tumour progression, not much is known about the various components and their effect on head and neck squamous cell carcinoma (HNSCC) progression. Levels of collagen type XI a1 (colXIa1), a minor fibrillar collagen, have been shown to be increased in tumour compared with normal tissue in several cancers, including colorectal, breast, and non-small cell lung cancer. Currently, the functional significance of colXIa1 is not understood.
Worldwide, head and neck cancer is the 6th leading cause of cancer mortality, with 350 000 deaths per year due to cancers of the oral cavity, pharynx, and larynx (Ferlay et al, 2008) . Over 630 000 new cases of head and neck cancer are diagnosed annually, of which 90% are squamous cell carcinoma (HNSCC). Treatment with standard modalities, including chemotherapy, radiation, and surgery, is associated with a 5-year survival rate of only 50%, emphasising the need for newer, more effective approaches (Cognetti et al, 2008) . Although cumulative evidence supports the epidermal growth factor receptor (EGFR) as a therapeutic target in HNSCC, where increased expression correlates with worse prognosis (Rubin Grandis et al, 1998) , treatment with the EGFRtargeted monoclonal antibody cetuximab has not been shown to prevent metastasis (Bonner et al, 2006) .
In a previous study, we used a 12 000 gene oligonucleotide microarray of paired tumour and normal tissue from nine HNSCC patients to determine differential gene expression in order to identify potential therapeutic targets (Sok et al, 2003) . Gene expression changes were found in 227 genes, including collagen type XI subunit a1 (colXIa1), which was found in all nine tumours with virtually no expression in normal tissue.
Type XI collagen, a minor fibrillar collagen, is a heterotrimer composed of a1, a2, and a3 chains that co-polymerise with type II and IX collagen to form the cartilage (Spranger, 1998) . The a1 subunit produced by non-cartilaginous tissues, such as bone, skin, and arterial smooth muscle cells, is located on chromosome 1 and regulates the promoter of the major collagen type V (COL5a2) (Yoshioka et al, 1995) . Although type XI collagenopathies at birth are known to produce phenotypes that include facial anomalies, cleft palate, and hearing defects (Spranger, 1998) , relatively little is known about the function of type XI collagen in the adult.
A 2001 study of colorectal tumours first identified an association between colXIa1 and cancer (Fischer et al, 2001b) . ColXIa1 mRNA expression was found in 20 of 24 colorectal tumours, whereas no apparent expression was found in the 4 normal tissue samples. In addition, COL5a2, which is normally expressed in human fetal gut and not expressed in the normal adult colon tissue, was correlated with the expression of colXIa1 in the colorectal tumours. Recent studies in several other areas of cancer research, including gastric (Vecchi et al, 2007; Zhao et al, 2009) , pancreatic (Badea et al, 2008) , breast (Ellsworth et al, 2009) , and non-small lung cancer (Chong et al, 2006) , have also demonstrated increased levels of colXIa1 in tumour tissue compared with less-diseased or normal tissue. In a multi-cancer computational analysis of four data sets of ovarian and colorectal cancer, the authors concluded that colXIa1 overexpression is a proxy for 'metastasis-associated fibroblast (MAF)' signature (Kim et al, 2010) .
Our initial observation of increased expression of colXIa1 in HNSCC was corroborated by another group whose findings also implicated colXIa1 in the pathogenesis of HNSCC metastasis to the lymph nodes (Schmalbach et al, 2004) . Primary tumours that had metastasised to the lymph nodes demonstrated over seven-fold higher expression of colXIa1 than tumours that had not metastasised and over 25-fold higher expression of colXIa1 than levels in normal oral cavity mucosa samples. Thus far, the precise role of colXIa1 in proliferation and invasion remains incompletely understood, and few functional data have been reported.
In the present study, we examined colXIa1 expression in a panel of HNSCC cell lines and a cohort of paired tumour/normal samples derived from HNSCC patients. We then used an siRNA approach to determine the role of colXIa1 in cellular proliferation, migration, and invasion.
MATERIALS AND METHODS
Cell lines, tumours, and reagents. Human HNSCC cell lines included UMSCC-1 (Krause et al, 1981) , UMSCC-10A (Grenman et al, 1991) , UMSCC-10B (Somers et al, 1992) , UMSCC-22A (Lansford et al, 1999) , and UMSCC-22B (Grenman et al, 1991) , which were kind gifts from Dr. Thomas Carey (University of Michigan); UPCI-15B (Snyderman et al, 1994) from Dr. Theresa Whiteside (University of Pittsburgh); 1483 (Sacks et al, 1988) from Dr. Peter Sacks (New York University); 686LN (Sturgis et al, 1994) from Dr. Georgia Chen (Emory University); and FaDu (Rangan, 1972) from Dr. Jeffrey Myers (The University of Texas MD Anderson Cancer Center). The Het1A (Stoner et al, 1991) cell line, derived from mucosal epithelial cells, was obtained from American Type Culture Collection (Manassas, VA, USA). All cell lines were validated through genotyping with an AmpF/STR Identifiler PCR Amplification Kit (Applied Biosystems, Carlsbad, CA, USA).
UMSCC-1 and FaDu cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen) and 0.4 ml ml À 1 hydrocortisone. 686LN cells were maintained in Dulbecco's modified Eagle's medium/F12 (1 : 1) (Invitrogen) and 10% FBS. Het1A cells were maintained in Airway Epithelial Cell Growth Media (PromoCell, Heidelberg, Germany) with a supplement provided by the company. All other cell lines including cancer-associated fibroblasts (CAFs), and normal fibroblasts were maintained in DMEM with 10% FBS. All cells were incubated at 37 1C in the presence of 5% CO 2 . Fibroblast cultures were growth from HNSCC tissue or from uvulopalatoplasty or tonsil explants from cancer-free subjects. Written consent was collected from patients, using a University of Pittsburgh, Institutional Review Board approved protocol. In brief, tissue pieces were minced and placed in 10% serum containing media. Fibroblast cultures free of epithelial cells were used in these studies.
Primary HNSCC tumour samples, as well as normal mucosal samples adjacent to the tumour site, were obtained under an institutional review board-approved protocol from 23 HNSCC patients undergoing surgical excision with curative intent (Table 1) . Signed informed consent was obtained from each subject. Human papilloma virus (HPV) status was not determined for majority of the patients (58%). All evaluated patients were HPV negative. RT-PCR analysis for colXIa1. Total RNA was isolated from 30 mg of snap-frozen tumour tissue as described previously using an RNeasy Mini kit (Qiagen, Valencia, CA, USA) (Sok et al, 2003) . One nanogram of total RNA was added to a final reaction volume of 25 ml. To detect colXIa1, standard RT-PCR was done using a One-Step RT-PCR kit (Qiagen) with primers (5 0 -GGATCAAA TGATGAGGAGATGTCCTATG-3 0 and antisense sequence as 5 0 -CTAAATGGTACCTGTATATGCAGCGTTG-3 0 ) designed to amplify a 345-bp fragment. Actin primers were used as previously described (Sok et al, 2006) . Primers were diluted to a final concentration of 0.6 mM. All other reagents were used according to the manufacturer's protocol. Reverse transcription was performed at 50 1C for 30 min, followed by enzyme inactivation and PCR hot start at 95 1C for 15 min. Denaturation, annealing, and extension were performed at 94 1C, 55 1C, and 72 1C, respectively, for 1 min each for a total of 35 cycles. The reaction was completed with an extension period at 72 1C for 10 min. PCR products were visualised on a 1% agarose gel containing ethidium bromide. Expression levels of colXIa1 and actin in the paired tumour and normal epithelial samples were compared using ImageJ densitometry software.
Total RNA was isolated from 5 Â 10 6 cells from each of the nine representative HNSCC cell lines (UMSCC-1, UMSCC-10A, UMSCC-10B, UMSCC-22A, UMSCC-22B, UPCI-15B, 1483, 686LN, and FaDu), normal mucosal epithelial cell line Het1A (5 Â 10 6 cells), and fibroblasts, using an RNeasy Mini kit (Qiagen). RT-PCR to detect colXIa1 was performed as described above. In vitro growth inhibition by colXIa1 siRNA. To examine the effects of colXIa1 on growth kinetics, UMSCC1 cells were treated with colXIa1 siRNA B or control non-targeting siRNA. Around 42 h post transfection, the cells were trypsinised and plated in xCelligence E-plates Roche (Indianapolis, IN, USA) as previously described (Hickok et al, 2011) . In brief, after baseline measurements, 2000 cells were plated in 200 ml DMEM þ 10% FBS in quadruplicates into 16-well E-plates. Cell index (difference between the impedance at a given time point and the background, divided average resistance across the plate in media only using 10 kHz frequency of current) measurements were taken every 15 min. The growth rates of the cells were assessed in real-time over 40 h on the xCelligence DP system. The fold-change in growth relative to the measurement at 5 h post plating was determined. The experiment was repeated three independent times.
Matrigel invasion assay and migration assay. Cell invasion was evaluated in vitro using Matrigel-coated semipermeable-modified Boyden inserts with a pore size of 8 mm (Becton Dickinson/Biocoat, Bedford, MA, USA). Cell migration was evaluated in vitro using semipermeable-modified Boyden inserts with a pore size of 8 mm (Becton Dickinson/Biocoat). Cells from HNSCC lines (UMSCC-1 and FaDu) and the normal cell line Het1A were transfected with siRNA-colXIa1 duplex B or non-targeting control siRNA (siRNA-NTC) as described above and plated in duplicate at a density of 1.25 Â 10 4 cells per well in serum-free media in the insert. The insert contained serum-free media, while the holding well contained 10% FBS that served as a chemoattractant. After 24 h of treatment at 37 1C in a 5% CO 2 incubator, the cells in the insert were removed by gentle wiping with a cotton swab. Cells on the reverse side of the insert were fixed and stained with Hema 3 (Fisher Scientific, Hampton, NH, USA) according to the manufacturer's instructions. Cells plated in 24-well plates were subjected to 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, and the cell numbers across the groups were normalised. A ratio of the number of invading/migrating cells to the OD from the MTT assay was determined in order to adjust for changes in cell number across wells.
Statistical analysis. Non-parametric, Wilcoxon-Mann-Whitney exact tests were used to compare effects on cell proliferation, invasion, and migration in cells treated with control or colXIa1 siRNA. In order to analyse the differences between levels of colXIa1 in the paired tumour and normal adjacent mucosa tissue samples from 23 patients, the exact Wilcoxon Signed rank test was used. All statistical analyses were performed with Cytel Studio 9 (Cytel, Inc., Cambridge, MA, USA).
RESULTS
Increased expression of colXIa1 in HNSCC tumours compared with levels in adjacent normal mucosa. Previous cDNA microarray analysis demonstrated that, although colXIa1 was present in tumour tissue from all nine HNSCC tumours examined, it was virtually undetectable in corresponding normal adjacent tissue (Sok et al, 2003) . The high incidence of synchronous and metachronous tumours of the upper aerodigestive tract that characterises HNSCC carcinogenesis suggests that molecular changes that are found in both the tumour and adjacent normal mucosa may represent relatively early genetic changes (Bedi et al, 1996; Scholes et al, 1998) . We sought to determine colXIa1 mRNA levels in tumour tissue compared with levels in paired adjacent normal tissue in 23 HNSCC patients using RT-PCR. In 16 of 23 pairs, colXIa1 expression was significantly higher in the tumour compared with normal tissue (P ¼ 0.0006) with a median fold increase of 6.63 (range 1.8-169), suggesting that increased colXIa1 represents a later event in HNSCC carcinogenesis (Figure 1 ). In the absence of specific antibodies of sufficiently high quality, we could not validate these expression results at the protein level. However, our results confirm earlier studies demonstrating increased expression of colXIa1 in HNSCC tumours.
Increased expression of colXIa1 in HNSCC cell lines compared with normal immortalised mucosal epithelial cells. Tumour lysates represent both epithelial and stromal cells in the tumour microenvironment. There are no reports of colXIa1 expression in cancer cell lines compared with corresponding normal cells. To determine if the transformed epithelial cells were the likely source of colXIa1 lines, we compared colXIa1 mRNA levels in nine genotypically validated, representative HNSCC cell lines (UMSCC-1, UMSCC-10A, UMSCC-10B, UMSCC-22A, UMSCC-22B, UPCI-15B, 1483, 686LN, and FaDu) with expression levels in immortalised normal mucosal epithelial cells (Het1A) by RT-PCR. Expression of colXIa1 was detected in all nine HNSCC cell lines examined compared with the corresponding normal cell line, which did not express colXIa1 transcript (Figure 2) . These results suggest that colXIa1 overexpression is, at least in part, due to increased expression in the transformed epithelial cell component of tumours.
Increased expression of colXIa1 in tumour-derived fibroblasts compared with fibroblasts from cancer-free subjects. It is well documented that, in response to wounds, normal fibroblasts secrete several types of collagen including colXIa1. Stromal expression of colXIa1 is associated with malignancy in colorectal cancer (Fischer et al, 2001b) . Higher levels of colXIa1 were reported in fibroblasts associated with lung cancer compared with normal fibroblasts (Navab et al, 2011) . HNSCC tumours are closely associated with fibroblasts. There are no reports on the levels of colXIa1 expressed by stromal fibroblasts in the head and neck region. Primary HNSCC cancer-associated fibroblasts and fibroblasts from cancer-free subjects were grown out of tissue explants. We examined the levels of colXIa1 in primary fibroblasts isolated from cancer-free patients and HNSCC explants. Our data demonstrate that the cancer-associated fibroblast express higher levels of colXIa1 compared with fibroblasts from cancer-free patients (Figure 3 ).
ColXIa1 contributes to HNSCC proliferation, migration, and invasion. Although colXIa1 has been shown to correlate with tumour size in non-small cell lung cancer (Chong et al, 2006) , the role of colXIa1 in cell growth has not been examined in cancer cells. We hypothesised that, if colXIa1 contributes to HNSCC proliferation, then knocking down colXIa1with siRNA would decrease cell proliferation in vitro. We transfected HNSCC cells with pooled siRNA targeting colXIa1 or GFP as a control, collected cells on days 2, 3, 4, and 5, and performed RT-PCR. Gene inactivation was observed on day 5 ( Figure 4A ). Next, we tested individual siRNA and determined that siRNA B demonstrated efficient knockdown of colXIa1 up to 48 h post transfection ( Figure 4B ).
The growth kinetics of cells transfected with siRNA-colXIa1 duplex B was compared with cells transfected with non-targeting siRNA. colXIa1 on transfection with siRNA duplex B significantly reduced cell proliferation compared with cells transfected with non-targeting control siRNA (P ¼ 0.014) ( Figure 5A ). These results suggest that colXIa1 contributes to cell proliferation in HNSCC cells in vitro.
ColXIa1 expression has been reported to be 7.61-fold higher in the primary HNSCC tumour in the setting of metastasis to the lymph nodes compared with levels in a primarily HNSCC tumour that remains confined to the head and neck mucosa (Schmalbach et al, 2004) . The role of colXIa1 in cell migration or invasion has not been studied. To determine if colXIa1 contributes to HNSCC migration in vitro, representative HNSCC cell lines (UMSCC-1 and FaDu) were transfected with colXIa1 duplex B siRNA or the non-targeting control siRNA (siRNA-NTC). We also assessed invasion using a Boyden Matrigel chamber assay. ColXIa1 knockdown in UMSCC-1 and FaDu cells resulted in reduced migration (P ¼ 0.05) and invasion (P ¼ 0.05), respectively ( Figure 5B and C) . Thus, colXIa1 is an important facilitator of HNSCC progression.
DISCUSSION
Type XI collagen, a minor fibril collagen, is a heterotrimer made up of a1(XI)-, a2(XI)-, and a3(XI) chains (Yoshioka et al, 1995) and accounts for B3% of the adult cartilage matrix (Eyre et al, 2006) . Molecules of collagen IX and XI stabilise collagen II, a major collagen, and limit its lateral growth (Blaschke et al, 2000) . The role of type XI collagen in the adult remains unclear, although recent evidence in numerous types of cancer implicates colXIa1 in carcinogenesis (Vecchi et al, 2007; Badea et al, 2008; Ellsworth et al, 2009; Kim et al, 2010) . Further, expression of colXIa1 is reported to be accompanied expression of genes associated with epithelial-to-mesenchymal transition (EMT) (Anastassiou et al, 2011) . We previously reported that colXIa1 was present in tumour tissue and was undetectable in corresponding normal adjacent tissue in a cDNA microarray analysis of tissue from nine HNSCC patients (Sok et al, 2003) . Microarray of paired tumour and normal tissue from 36 patients with pancreatic ductal adenocarcinoma revealed greater than two-fold overexpression of colXIa1 in tumour tissue compared with normal tissue (Badea et al, 2008) . RT-PCR of paired tumour and normal tissue from 70 pairs of patients with non-small cell carcinoma demonstrated 3.4-fold higher expression of colXIa1 in tumour tissue (Chong et al, 2006) . Similarly, RT-PCR of paired malignant and premalignant tissue from 21 patients with gastric cancer showed increased levels of colXIa1 in malignant tissue (Zhao et al, 2009) , and RT-PCR of polyps and normal tissue from 1 patient with familial adenomatous polyposis showed increased colXIa1 expression in the polyps (Fischer et al, 2001a) . Most of the reports on colXIa1 in cancer represent correlative studies; thus, to our knowledge, this is the first investigation of the functional significance of colXIa1 overexpression in any type of cancer.
Collagens in general are important components of the extracellular matrix. It has been shown that collagen cross linking increases ECM stiffness and promotes tumorigenesis in breast cancer and that reduction in collagen cross linking leads to a decrease in tumour incidence (Blaschke et al, 1994) . We undertook the present study to determine the role of colXIa1 in proliferation, migration, and invasion of head and neck cancer. Our results suggest that colXIa1 expression is increased in HNSCC tumours and cell lines compared with levels in normal tissue or immortalised epithelial cells. Further investigation demonstrated that colXIa1 contributes to the proliferation, migration, and invasion of head and neck cancer cells in vitro.
HNSCC carcinogenesis is characterised by a high incidence of synchronous and metachronous tumours, suggesting that molecular changes that are found in both the tumour and adjacent normal mucosa represent relatively early genetic changes (Bedi et al, 1996; Scholes et al, 1998) . In this study, we found that colXIa1 expression by RT-PCR was higher in tumour compared with normal tissue in paired samples in 16 of 23 HNSCC patients, indicating that increased colXIa1 expression is a later event in HNSCC carcinogenesis. Our findings are consistent with previous findings of increased colXIa1 in tumour compared with normal tissue in paired samples from 70 patients with nonsmall cell lung carcinoma and in malignant tissue compared with pre-malignant tissue in paired specimens from 21 patients with gastric cancer (Zhao et al, 2009) . Our attempts at generating a polyclonal antibody to colXIa1 were not successful primarily because of the paucity of unique antigenic epitopes. Lack of specific antibodies limited our ability to assess protein levels of colXIa1 in tissue and cell lines. Because changes in the stromal tumour microenvironment are thought to contribute to invasion and spread of tumours (De Wever and Mareel, 2003) , we compared the expression levels of colXIa1 in cancer-associated fibroblasts and normal oral fibroblasts derived from cancer-free patients. We found that cancer-associated fibroblasts had higher levels of colXIa1 compared with normal oral fibroblasts. The cancer-associated fibroblasts and normal oral fibroblasts used in these studies were primary cells derived from fresh tissue. These cells are cultured for up to 10 passages and retain their fibroblast morphology. However, it cannot be ruled out that HNSCC cells that have undergone epithelial-to-mesenchymal transition are present among the cancer-associated fibroblast cultures. The data suggest that changes in mesenchymal cells in the HNSCC microenvironment are associated with increased levels of colXIa1, a finding that is at odds with Halsted et al (2008) , who found that colXIa1 was downregulated in stroma surrounding breast cancer. In another study of breast cancer, however, higher levels of colXIa1 expression in primary breast tumours than in corresponding metastatic lymph node tumours were reported and concluded that the overexpression of genes in the primary tumours were involved with extracellular matrix degradation and contributed to metastatic spread of the tumour (Ellsworth et al, 2009) . Further, it has been proposed that interaction between breast and colon cancer cells with the microenvironment triggers expression of mesenchymal signature genes including colXIa1 (Cheng et al, 2013) .
We sought to determine if increased colXIa1 expression was derived from the transformed epithelial cells and/or stromal cells in the tumour microenvironment. To date, there is no literature on colXIa1 expression in cancer cell lines compared with normal cells. We compared colXIa1 mRNA levels in nine validated, representative HNSCC cell lines using RT-PCR and found that expression was increased in all nine HNSCC cell lines, whereas the corresponding normal cells did not express the colXIa1 transcript. Thus we conclude that both the tumour and stromal fibroblast cells contribute to the high levels of collXIa1 in HNSCC tissue.
Although studies of gastric, lung, ovarian, and colorectal carcinomas have implicated the role of colXIa1 overexpression in more advanced disease (Schmalbach et al, 2004; Vecchi et al, 2007; Zhao et al, 2009; Kim et al, 2010) , only one study has correlated colXIa1 and tumour size (Chong et al, 2006) . Further, no direct investigation has been undertaken to examine the role of colXIa1 in cellular proliferation of cancerous or normal cells. We postulated that by knocking down colXIa1 in HNSCC cells in vitro, proliferation would decrease. We transfected a representative HNSCC cell line (UMSCC-1) with siRNA directed against colXIa1 and demonstrated decreased colXIa1 expression by RT-PCR. We then demonstrated that cellular proliferation of UMSCC-1 cells decreased in the siRNA-colXIa1-transfected cells in comparison with the control. In contrast, normal Het1A cells did not display a decrease in proliferation after transfection with siRNA-colXIa1. Therefore, these results suggest that colXIa1 overexpression does, in fact, contribute to cellular proliferation in cancer cells and that knockdown of colXIa1 abrogates cell growth in cancer cells but not normal cells. ColXIa1 has been implicated in metastasis, with one study demonstrating higher levels of colXIa1 in primary tumours of the head and neck that have metastasised to the lymph node compared with tumours that remain confined to the primary site (Schmalbach et al, 2004) . Cellular migration and invasion are thought to contribute to metastasis. No studies to date have examined the role of colXIa1 on cell motility of any type. We assessed the role of colXIa1 in invasion and migration in UMSCC-1 and Het1A cells that had been transfected with siRNAcolXIa1. We demonstrated that knocking down colXIa1 decreases migration and invasion in the HNSCC cell lines UMSCC-1 but not in the normal cell line Het1A. Thus, colXIa1 not only contributes to proliferation but also to invasion and migration as well in cancer cells, with no effect on normal cells.
Patients with HNSCC, like many epithelial cancers, succumb to disease that has metastasised. The precise mechanisms of HNSCC metastasis, including migration and invasion remain incompletely understood. The results of the present study suggest that colXIa1 has a role in mediating the proliferation, invasion, and migration of cancer cells, underscoring the need for further investigation of this collagen in carcinogenesis.
